Pluri and ZEO ScientifiX strike U.S. regenerative medicine partnership

Pluri and ZEO ScientifiX said Oct. 26 they signed a definitive agreement to combine Pluri’s cell technology with ZEO’s U.S. biologics manufacturing and commercial platform. The deal is designed to expand products, including regenerative aesthetics, and could give Pluri 50% ownership of ZEO at closing.

Why it matters: - The partnership is designed to give Pluri faster access to a U.S. commercial channel in regenerative medicine, aesthetics, wellness and longevity. - ZEO brings an existing physician network, sales force and manufacturing base that can help new products reach market. - Pluri brings cell-technology expertise, clinical-development experience and scalable manufacturing know-how that can support product expansion.

What happened: - Pluri Inc. and ZEO ScientifiX announced a definitive strategic agreement on Oct. 26, 2026, to expand their U.S. manufacturing and commercialization platform. - The companies said the deal combines Pluri’s proprietary cell technology and development experience with ZEO’s biologics manufacturing expertise and commercial infrastructure. - The agreement is intended to support regenerative medicine, aesthetics, wellness and longevity markets.

The details: - ZEO contributes an established U.S. biologics business, including scientific and manufacturing capabilities, an existing product portfolio, a substantial physician network, a sales channel, a marketing department and educational programming. - Pluri contributes more than two decades of experience in cell-based research, product development, clinical trials, process scale-up, quality systems and manufacturing. - Pluri’s proprietary 3D cell-expansion technology and intellectual property support development and manufacturing of cell-based products, including CellaV regenerative aesthetics products. - The agreement gives ZEO exclusive U.S. rights to Pluri’s CellaV aesthetic product line, including future offerings. - CellaV, Pluri’s wholly owned aesthetics subsidiary, develops cell-derived ingredients and aesthetic products. - Pluri said it has more than two decades of clinical-development expertise, including multinational Phase III trials in muscle recovery following hip-fracture surgery and critical limb ischemia. - Pluri also said its intellectual property portfolio includes more than 200 patents. - Under the transaction, Pluri will grant ZEO defined rights to its manufacturing technology and related know-how tied to regenerative-medicine assets, while Pluri retains ownership of its underlying technology and intellectual property. - ZEO will initially issue common stock representing 50% of its issued and outstanding shares immediately after closing. - The agreement also includes warrants, corporate governance and protective rights, plus customary representations, warranties, covenants and indemnifications. - After closing, ZEO’s financial results are expected to be consolidated into Pluri’s financial statements, subject to accounting requirements. - Pluri said the contemplated additional share exchange will leave Pluri owning 50% of ZEO at closing after the required transaction steps.

Between the lines: - The structure suggests both companies want more than a simple licensing deal; they are building a shared platform with commercial and development upside. - Pluri gains a direct route into U.S. distribution and physician relationships, which can matter as much as the science in regenerative medicine. - ZEO gains access to proprietary cell technology and late-stage development experience that could deepen its product pipeline.

What's next: - The companies expect closing in the fourth quarter of 2026. - Closing still depends on negotiation of ancillary agreements, required approvals, valuations and other customary conditions. - The transaction does not require stockholder approval from either company. - The companies said they will pursue expanded commercialization and selected regenerative-development programs subject to applicable regulatory requirements.

The bottom line: - Pluri and ZEO are trying to pair science with distribution: Pluri supplies cell technology and development depth, while ZEO supplies U.S. manufacturing and market access.